| Accelerating APAC Expansion with an AI-Based Clinical Trial Data Management Platform
JNPMEDI, an AI-driven clinical trial data platform and consulting company specializing in drug and innovative medical device development, announced that it has been officially selected for the 2025 Global TIPS (Tech Incubator Program for Startup) Commercialization Program (2nd round) led by Korea’s Ministry of SMEs and Startups. Through this selection, the company will accelerate its expansion into the Asia-Pacific (APAC) market.
The Global TIPS program supports promising startups that have secured at least USD 300,000 in investment from overseas venture capital firms, providing commercialization funding and global market entry programs. JNPMEDI’s selection recognizes the technological strength and global scalability of its AI-based clinical trial data platform.
JNPMEDI is advancing its APAC expansion strategy centered on its flagship solution, Maven Clinical Cloud. The platform is a B2B SaaS-based clinical trial data management solution that integrates advanced digital technologies such as AI, cloud computing, and blockchain. It offers a unified suite of services—including electronic case report forms (eCRF), electronic protocols (eProtocol), and electronic informed consent (eConsent)—to fully digitalize the clinical trial lifecycle. By automating data entry and review processes, the platform reduces operational burden for researchers while enhancing data quality and reliability, ultimately improving overall clinical trial efficiency. The company aims to significantly shorten the time and cost required for drug and innovative medical device development.
The APAC region is widely regarded as a strategic hub for global pharmaceutical and biotech companies, driven by cost efficiency, rapid patient recruitment, and ethnic diversity. Leveraging these market advantages, JNPMEDI plans to continuously strengthen its competitiveness in platform-based digital transformation for clinical trials.
“Being selected for the Global TIPS program marks an important milestone for us,” said KwunHo Jeong, CEO of JNPMEDI. “We will further advance the technical maturity and scalability of Maven Clinical Cloud and continue expanding the adoption of digital technologies across global clinical trial environments, including the APAC region.”
| Accelerating APAC Expansion with an AI-Based Clinical Trial Data Management Platform
JNPMEDI, an AI-driven clinical trial data platform and consulting company specializing in drug and innovative medical device development, announced that it has been officially selected for the 2025 Global TIPS (Tech Incubator Program for Startup) Commercialization Program (2nd round) led by Korea’s Ministry of SMEs and Startups. Through this selection, the company will accelerate its expansion into the Asia-Pacific (APAC) market.
The Global TIPS program supports promising startups that have secured at least USD 300,000 in investment from overseas venture capital firms, providing commercialization funding and global market entry programs. JNPMEDI’s selection recognizes the technological strength and global scalability of its AI-based clinical trial data platform.
JNPMEDI is advancing its APAC expansion strategy centered on its flagship solution, Maven Clinical Cloud. The platform is a B2B SaaS-based clinical trial data management solution that integrates advanced digital technologies such as AI, cloud computing, and blockchain. It offers a unified suite of services—including electronic case report forms (eCRF), electronic protocols (eProtocol), and electronic informed consent (eConsent)—to fully digitalize the clinical trial lifecycle. By automating data entry and review processes, the platform reduces operational burden for researchers while enhancing data quality and reliability, ultimately improving overall clinical trial efficiency. The company aims to significantly shorten the time and cost required for drug and innovative medical device development.
The APAC region is widely regarded as a strategic hub for global pharmaceutical and biotech companies, driven by cost efficiency, rapid patient recruitment, and ethnic diversity. Leveraging these market advantages, JNPMEDI plans to continuously strengthen its competitiveness in platform-based digital transformation for clinical trials.
“Being selected for the Global TIPS program marks an important milestone for us,” said KwunHo Jeong, CEO of JNPMEDI. “We will further advance the technical maturity and scalability of Maven Clinical Cloud and continue expanding the adoption of digital technologies across global clinical trial environments, including the APAC region.”